during the speedily evolving discipline of oncology research, accurate and productive mutation screening is vital for producing targeted therapies. The KRAS providers System performs a pivotal role in this landscape by featuring extensive methods for KRAS mutation profiling and analysis. KRAS mutations, located in approximately ninety five% of RAS-